Patents Examined by Shirley V. Gembeh
  • Patent number: 10813879
    Abstract: The present disclosure relates to a formulation of a shampoo conditioner composition comprising water, flaxseed, olive oil, jojoba oil, emu oil, honey, and preservatives. This composition provides desirable characteristics such as increased moisture and non-comedogenic effects.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: October 27, 2020
    Assignee: Haute Herbotique, LLC
    Inventor: Marlene M. Smith
  • Patent number: 10806140
    Abstract: An antimicrobial composition including low molecular weight dendrimers of formula (1): Q is an antimicrobial moiety in monomer or dendritic form, N is a nitrogen atom, L2 is a linker linking each Y1 molecular spacer to the nitrogen atom, Y1 is a molecular spacer spacing each antimicrobial moiety Q from the L2 linker, there are two or more chains of antimicrobial moieties and molecular spacers, X is a linker configured to covalently bond to surface functionalities of the substrate, and Y2 is a molecular spacer between the linker X and the nitrogen atom.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: October 20, 2020
    Assignee: Physical Sciences, Inc.
    Inventors: Dorin V. Preda, Aaron R. Rathmell, Colin M. Hessel, John D. Lennhoff, Mitchell T. Antalek
  • Patent number: 10799435
    Abstract: Skin-tightening compositions and methods for using the same, which provide a long-lasting skin-tightening effect and a mattifying finishing effect are described. The skin-tightening composition may be in the form of an oil-in-water emulsion and comprise one or more polyvalent silicates; one or more cellulose thickeners; one or more clays selected from hectorite and organically modified hectorites; one or more polysaccharide film forming agents; one or more polyols; one or more acrylate polymers; and water. The skin-tightening compositions are useful for improving the appearance of skin, especially skin of the neck and face.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 13, 2020
    Assignee: L'OREAL
    Inventors: Mariana Montoya, Nicole Burkhard, David Chan, Maggie Su
  • Patent number: 10792234
    Abstract: The present invention relates to an in particular cosmetic or dermatological compositions comprising, in a physiologically acceptable support: • a) at least one merocyanine of formula (1) or (2) (1), (2) • b) at least one oily phase comprising at least one polyalkylene glycol of formula (4): (4) and to their use for caring for and/or making up a keratin material.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: October 6, 2020
    Assignee: L'OREAL
    Inventors: Didier Candau, Angelina Roudot
  • Patent number: 10792244
    Abstract: Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanoparticles, and polymeric microparticles or nanoparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: October 6, 2020
    Assignee: ASCENDIA PHARMACEUTICALS, LLC.
    Inventors: Vera Ivanova, Kaoru Maeda, Wan Wang, Dongwei Guo, Jingjun Huang
  • Patent number: 10786445
    Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: September 29, 2020
    Assignee: Biogen Chesapeake LLC
    Inventor: Sven Martin Jacobson
  • Patent number: 10772898
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: September 15, 2020
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 10774067
    Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 15, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Koji Shiraki, Tadanobu Nakayama, Tomoaki Ota
  • Patent number: 10765608
    Abstract: The present invention relates to a sprayable composition for providing a translucent, transparent, semi-transparent or opaque sprayable hair product which exhibits a high level of hold and rigidity to hair such that hair can be held in a particular position for prolonged periods of time without unnatural hardness, superior retention of shape in conditions of heat and humidity, and imparting thickness and body compared to current hairsprays; the composition comprising: a propellant and at least one binder, wherein at least one binder comprises an ethylene vinyl alkanoate copolymer with a weight percent of vinyl alkanoate in the copolymer within the range of 19 wt % to 42 wt %.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 8, 2020
    Inventor: Manel Torres
  • Patent number: 10766886
    Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 8, 2020
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
  • Patent number: 10759783
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 1, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • Patent number: 10759865
    Abstract: The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 1, 2020
    Inventor: Eyal Levit
  • Patent number: 10751285
    Abstract: A drug delivery system comprising the synthesis of resorcinarene based novel amphiphilic supramolecular macrocycle that is capable of self-assembling in nano-scale vesicles upon its contact with aqueous medium and its use as nano-drug loading vehicle when mixed with cholesterol (2:1 ratio w/w).
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: August 25, 2020
    Inventors: Muhammad Raza Shah, Imdad Ali, Heyam Saad Ali, Babiker M. El-Haj, Muhammad Imran
  • Patent number: 10744138
    Abstract: A hair growth formulation includes minoxidil and foeniculum vulgare, atriplex nummularia extract, or a combination of foeniculum vulgare and atriplex nummularia extract. A method for increasing hair growth includes applying a hair growth formulation to a subject.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: August 18, 2020
    Assignee: GARUHDA LLC
    Inventor: David Ben Kunin
  • Patent number: 10745403
    Abstract: Generally, the present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: August 18, 2020
    Assignee: PIMERA, INC.
    Inventor: Mustapha Haddach
  • Patent number: 10736892
    Abstract: Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-?) for inhibiting the growth of PKC-?-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: August 11, 2020
    Assignee: EpiAxis Therapeutics Pty Ltd.
    Inventors: Sudha Rao, Anjurn Zafar
  • Patent number: 10736881
    Abstract: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 11, 2020
    Assignee: MEI Pharma, Inc.
    Inventors: DiZhong Chen, Hong Yan Song, Eric T. Sun, Niefang Yu, Yong Zou
  • Patent number: 10736865
    Abstract: Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: August 11, 2020
    Assignee: RETINAGENIX THERAPEUTICS, INC.
    Inventor: Ronald Erwin Boch
  • Patent number: 10738054
    Abstract: The present invention relates to a composition of enantiomers of 3,6,7,7a-tetrahydro-1H-pyrrolo[1,5-a]imidazole-2,5-dione and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 11, 2020
    Assignee: METYS PHARMACEUTICALS AG
    Inventors: Michael Scherz, Carlo Farina
  • Patent number: 10730880
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: August 4, 2020
    Assignees: Array BioPharma Inc., Celgene Corporation
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett